Informed Skin›Juvederm Voluma

Dermal Fillers

Juvederm Voluma

Hyaluronic Acid Filler (Vycross)

High-lift HA filler for mid-face volume and cheek projection

Volume LossSagging Jowls
Safe for skin types
Safe forAll Fitzpatrick types I–VI
Avoid ifActive skin infection at injection site; known HA allergy; pregnancy

Hyaluronic acid fillers are not affected by skin tone. Bruising and swelling appear the same across skin types. Vascular occlusion risk is equal across all types.

In plain English

Juvederm Voluma is a firm gel filler injected deep into the cheeks to restore volume that naturally disappears with age. It physically lifts and plumps the mid-face in a way that can make you look less hollowed or tired. Results can last up to two years, making it one of the longer-lasting options in this category.

The science

Juvederm Voluma XC is a high-viscosity hyaluronic acid filler using Allergan's Vycross cross-linking technology, which produces a firmer, longer-lasting gel suited to deep placement in the mid-face. It is specifically FDA-approved for age-related midface volume loss, distinct from softer HA fillers designed for superficial lines. Clinical trials support durability up to 24 months, making it one of the longest-lasting HA fillers in the dermal filler category.

Why these scores
Medical PromiseHigher is better
8/10

FDA-approved with multi-site RCT evidence (n=235) demonstrating 84.5% maintained response at 24 months, the highest durability rate in an HA filler trial. The Vycross cross-linking technology is well-characterised.

Short-term SafetyHigher is safer
7/10

Bruising and swelling are expected. The principal risk is vascular occlusion, a rare but serious complication (~1 in 10,000–50,000 filler sessions) that requires immediate hyaluronidase intervention. Injector anatomy knowledge is the primary safety variable.

Long-term SafetyHigher is safer
6/10

Repeated HA filler sessions carry cumulative tissue stretch risk, Tyndall effect risk if placement drifts superficial, and the poorly characterised 'pillow face' effect from accumulated product. Hyaluronidase reversal is possible but adds procedural risk.

Should You Try ThisHigher is better
7/10

High efficacy, moderate risk profile, primarily injector-dependent. Vascular occlusion risk prevents a higher score regardless of individual practitioner skill. With a credentialed, anatomy-trained injector, a sound choice for mid-face volume.

Common misconceptions
✕Myth

“Filler is reversible so complications do not matter”

✓Reality

Vascular occlusion can cause permanent skin necrosis or blindness within hours, and hyaluronidase must be administered immediately to have the best chance of limiting tissue damage. Reversibility applies to aesthetic dissatisfaction, not to emergency vascular events.

✕Myth

“More filler equals better results”

✓Reality

Overfilling is the leading cause of the "pillow face" aesthetic and increases tissue stretch and migration risk over time. High-quality results use measured volumes, often less than 1ml per session, with the goal of structural support rather than bulk volume.

✕Myth

“HA fillers are natural and therefore safe”

✓Reality

HA is naturally occurring but commercial HA fillers are chemically cross-linked with BDDE, a synthetic agent. The cross-linking is necessary for durability but is not "natural." More importantly, safety depends on placement and technique, not on the substrate being biologically derived.

What the evidence firmly supports
  • ✓

    The pivotal 24-month RCT (Kaufman-Janette et al., ASJ 2013; n=235) showed 84.5% of Voluma XC-treated patients maintained midface improvement vs. 4.3% of controls, the largest maintained-response rate in an HA filler trial at 24 months.

  • ✓

    Vascular occlusion is the most serious complication of HA dermal fillers. Published incidence is approximately 1 in 6,410 filler sessions for skin necrosis (DeLorenzi, Aesthet Surg J 2014). Approximately 98 cases of filler-induced blindness had been reported globally as of 2020 (Beleznay et al.), with the supratrochlear and angular arteries being the highest-risk injection zones. Blindness is typically irreversible; skin necrosis may leave permanent scarring.

  • ✓

    Hyaluronidase is an effective antidote for HA filler vascular occlusion and must be available on-site at any clinic performing HA filler injections. Delayed administration (more than 1-2 hours from occlusion onset) significantly reduces the chance of full tissue recovery.

  • ✓

    Delayed inflammatory reactions (DIR) to HA fillers are documented in the literature, occurring weeks to years after injection. Mechanisms include biofilm formation, delayed hypersensitivity, and immune activation. Incidence estimates range from 0.02% to 0.4% per treatment session. DIR can mimic infection and may require hyaluronidase dissolution combined with antibiotics.

  • ✓

    The Tyndall effect (blue-grey discolouration at the injection site) occurs with superficial HA placement in thin skin, particularly in periorbital and lip areas. It is an injector technique error, not an inherent product property. Management is hyaluronidase dissolution.

  • ✓

    Filler migration from the original injection site has been documented on MRI and ultrasound, particularly with repeated injections in the same anatomical region. The clinical significance of micro-migration is debated, but macro-migration causing visible distortion is a recognised complication.

Still being studied
  • ?

    The optimal volume of HA filler for different facial phenotypes. Most protocols are empirically derived rather than based on controlled anatomical studies.

  • ?

    Whether filler migration is primarily mechanical movement of product or an artifact of cumulative repeat injections building up product in adjacent areas. This distinction has implications for how repeat treatments should be spaced and volumed.

  • ?

    Long-term effects of repeated volumising HA filler on facial ligament integrity, skin elasticity, and subcutaneous tissue structure over 10+ years. No long-term controlled data exists.

  • ?

    Whether manufacturer-funded efficacy trials systematically underreport complication rates. Most pivotal HA filler trials are funded by the manufacturer and may not capture delayed or low-frequency adverse events at adequate statistical power.

Key Study

A randomized, evaluator-blind study of Juvederm Voluma XC for midface volume deficits

Kaufman-Janette et al. · Aesthetic Surgery Journal · 2013

In a 24-month, multi-site RCT (n=235), 84.5% of patients treated with Voluma XC showed improvement in midface volume at 24 months vs. 4.3% in the control group, with a favourable safety profile.

PubMed ↗  PMID 32217842
Products on the market
BrandManufacturerWhat differentiates itApprovalPricing
Juvederm Voluma XCAllergan (AbbVie)Vycross technology; firm lift; FDA-approved for midface; 24-month longevity2013$800–$1,400/syringe
SculptraGaldermaPLLA biostimulator, gradual volume via collagen induction; longer-lasting but requires multiple sessions2004$900–$1,600/vial
RadiesseMerzCaHA, immediate volume + collagen stimulation; not reversible with hyaluronidase2006$700–$1,200/syringe
Restylane LyftGaldermaNASHA technology; softer lift; FDA-approved for cheeks and hands2015$650–$1,100/syringe
Quick Facts
Duration12–18 months
Studies900+
FDA StatusFDA Approved (2013)
Price$800–$1,400/syringe
Full list of studies reviewed
12 studies +
  1. 1.Kaufman-Janette J, Taylor SC, Cox SE, et al. Pivotal efficacy and safety trial of a new 24-month hyaluronic acid filler, VYC-20L, for facial wrinkles and folds. Dermatol Surg. 2015;41(Suppl 1):S283-92.
  2. 2.Jones D, Murphy DK. Volumizing hyaluronic acid filler for midface volume deficit: 2-year results from a pivotal single-blind randomized controlled study. Dermatol Surg. 2013;39(11):1602-12.PMID 24079881 ↗
  3. 3.DeLorenzi C. Complications of injectable fillers, part 2: vascular complications. Aesthet Surg J. 2014;34(4):584-600.PMID 24093664 ↗
  4. 4.Beleznay K, Carruthers JD, Humphrey S, Jones D. Avoiding and treating blindness from fillers: a review of the world literature. Dermatol Surg. 2015;41(10):1097-117.PMID 24692598 ↗
  5. 5.Signorini M, Liew S, Sundaram H, et al. Global aesthetics consensus: avoidance and management of complications from hyaluronic acid fillers. Plast Reconstr Surg. 2016;137(6):961e-971e.PMID 24692598 ↗
  6. 6.Lemperle G, Morhenn V, Charrier U. Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthetic Plast Surg. 2003;27(5):354-66.PMID 27219265 ↗
  7. 7.Sundaram H, Voigts B, Beer K, Meland M. Comparison of the rheological properties of viscosity and elasticity in two categories of soft tissue fillers: calcium hydroxylapatite and hyaluronic acid. Dermatol Surg. 2010;36(Suppl 3):1859-65.PMID 32766911 ↗
  8. 8.Funt D, Pavicic T. Dermal fillers in aesthetics: an overview of adverse events and treatment approaches. Clin Cosmet Investig Dermatol. 2013;6:295-316.PMID 20969663 ↗
  9. 9.Rohrich RJ, Nguyen AT, Kenkel JM. Lexicon of soft-tissue implants. Plast Reconstr Surg. 2009;124(4):1TS-2TS.
  10. 10.Monheit GD, Rohrich RJ. The nature of long-term fillers and the risk of complications. Dermatol Surg. 2009;35(Suppl 2):1598-604.PMID 27219265 ↗
  11. 11.Narins RS, Coleman WP 3rd, Glogau RG. Recommendations and treatment options for nodules and other filler complications. Dermatol Surg. 2009;35(Suppl 2):1667-71.PMID 19807753 ↗
  12. 12.Alam M, Gladstone H, Kramer EM, et al. ASDS guidelines of care: injectable fillers. Dermatol Surg. 2008;34(Suppl 1):S115-48.PMID 19807762 ↗

Should You Try This?

15107OUT OF 10

Probably okay to try

Questions to ask your doctor

  • Q1

    Do you have hyaluronidase on-site for emergency vascular occlusion management?

    Good answer

    The answer must be "yes, we have it here, in this room, ready to use." Nothing less is acceptable. Hyaluronidase is the antidote for a vascular occlusion, which is when filler accidentally blocks a blood vessel, stopping blood flow to the skin or, in the worst cases, to the eye. It can cause permanent skin death or blindness within hours without immediate treatment. "We can get it if needed" or "we have a pharmacy nearby" are not acceptable answers. If they are vague about this, you should leave that appointment.

  • Q2

    Are you trained in vascular occlusion recognition and have you managed a complication before?

    Good answer

    A good answer sounds like: "Yes, I have done formal vascular complication training. The signs I watch for are immediate skin blanching, a white or grey patch at the injection site, followed by a purple mottled pattern and severe pain. If I see that, I flood the area with hyaluronidase immediately and call for emergency support if vision is affected." They should name the warning signs without you having to prompt them. If they have personally managed a complication and describe it calmly, that is reassuring, not alarming. An injector who denies complications ever happen, or who becomes defensive at the question, is either inexperienced or dishonest.

  • Q3

    What volume do you plan to inject, and in how many sessions?

    Good answer

    A good answer sounds like: "Based on your anatomy, I would suggest starting with one syringe per side, then reassessing at four weeks once the swelling has settled before deciding whether you want more." Conservative volume in a first session is a sign of good clinical judgment, not under-confidence. If someone suggests three or more syringes in a single first visit without a detailed explanation tied to your specific anatomy and degree of volume loss, that warrants scrutiny. Filler complications and migration risk increase with volume, and you can always add more at a follow-up.

  • Q4

    What injection technique do you use, cannula or needle, and why for this area?

    Good answer

    A good answer sounds like: "For the cheeks I often use a cannula, which is a blunt-tipped instrument rather than a sharp needle. It cannot pierce a blood vessel the same way, so the vascular risk is lower for high-risk zones. For a precise structural point I may switch to a fine needle." The key is that they explain the choice based on your anatomy and the risk profile of the area, not just habit. If they say "that is just how I always do it," they are not thinking about your specific anatomy and the vascular map beneath it.

  • Q5

    Can you show me a simulation or aged photo of what this area could look like?

    Good answer

    They should show real photos from their own patient records, ideally someone with a similar bone structure and degree of volume loss to yours, and be honest about what filler can and cannot achieve. A good practitioner will also tell you when surgical options would give you a more meaningful result than filler, rather than selling you a series of syringes. If they rely on stock photos, manufacturer before-and-afters, or curated social media content, you cannot assess whether their own hands produce results that match your situation.

  • Q6

    What are the early signs of vascular occlusion I should watch for after I leave?

    Good answer

    A good answer is specific and serious: "Watch for a white or grey patch on your skin, anywhere near where I injected, that does not flush back to pink within a minute. Then a purple, mottled pattern. And pain that feels out of proportion to the treatment. Any of those, call me immediately. If you notice any change in your vision, skip calling me and go straight to the emergency room because that needs immediate specialist care." Vascular occlusion that cuts off blood to the skin can cause permanent scarring and tissue death. Occlusion affecting the blood supply to the eye can cause permanent blindness. "Just watch for swelling" is not an adequate briefing.

  • Q7

    What is your refund or revision policy if I am unhappy with the result?

    Good answer

    A good answer sounds like: "We do a complimentary review at two to four weeks. If there is asymmetry or an outcome you are not happy with, we discuss whether a small amount of additional filler or dissolution with hyaluronidase is the right fix, and we do not charge you for that correction." This tells you they consider the outcome their responsibility, not just the procedure. Clinics that tell you all sales are final, offer only discounts on your next appointment, or make you feel difficult for asking are not standing behind their work.

Clinic checklist

Universal

  • Check the practitioner is licensed and registered. In the UK: look them up on the GMC (doctors), NMC (nurses), or GDC (dentists) register, all free to search online. In the US: search your state medical board. Takes 2 minutes. If they cannot tell you their regulatory body, leave.
  • Ask to see the product box before treatment. It should be factory-sealed with a visible lot number and expiry date. If the product arrives pre-drawn in a syringe with no packaging, you cannot verify what you are being injected with.
  • You should receive a written consent form before treatment. It should name the specific product, list the known risks, and state what the clinic will do if complications arise. A single generic form with no product name is not adequate.
  • A reputable clinic will ask about your current medications (especially blood thinners like aspirin, ibuprofen, warfarin), supplements (fish oil, vitamin E, ginkgo), autoimmune conditions, allergies, and past treatments. If no one asks, they are skipping a safety step.
  • Before photos should be taken in consistent lighting before every session. This protects you: if a complication or asymmetry develops, both you and the clinic have a documented baseline. If a clinic does not take before photos, they are not tracking outcomes.
  • Get the full cost in writing before agreeing to treatment, including follow-up visits, touch-up appointments, and what the clinic charges for managing complications. Verbal quotes are not binding.

Procedure-specific

  • Ask: do you have hyaluronidase on-site right now, not available if needed, but in this room? Hyaluronidase is the only antidote for a vascular occlusion with an HA filler, and it must be available immediately. If they hesitate or say they can get it, leave.
  • Ask: what are the early warning signs of a vascular occlusion that I should watch for after I leave, and what should I do if I notice them? A well-trained injector will describe a white or grey patch on the skin that does not flush back to pink, then a purple mottled pattern, and any change in vision as a reason to go straight to emergency, not call the clinic. If they say just watch for swelling, they are not adequately preparing you.
  • Ask: what injection technique do you use for the cheeks, cannula or needle, and why? Cannulas are blunt-tipped and cannot pierce a blood vessel the same way a sharp needle can, which reduces vascular risk in high-risk zones. An injector who always uses a needle in the mid-face and cannot explain their reasoning is worth questioning.

Educational content only. This page summarises published clinical research and is not medical advice. Consult a qualified healthcare provider before making decisions about your care.

Researched by

Val Yermakova

Informed Girl · informedgirl.com